These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24461709)

  • 1. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.
    Schnabel LV; Pezzanite LM; Antczak DF; Felippe MJ; Fortier LA
    Stem Cell Res Ther; 2014 Jan; 5(1):13. PubMed ID: 24461709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
    Berglund AK; Schnabel LV
    Equine Vet J; 2017 Jul; 49(4):539-544. PubMed ID: 27862236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.
    Pezzanite LM; Fortier LA; Antczak DF; Cassano JM; Brosnahan MM; Miller D; Schnabel LV
    Stem Cell Res Ther; 2015 Apr; 6(1):54. PubMed ID: 25889095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response to allogeneic equine mesenchymal stromal cells.
    Kamm JL; Riley CB; Parlane NA; Gee EK; McIlwraith CW
    Stem Cell Res Ther; 2021 Nov; 12(1):570. PubMed ID: 34772445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential.
    Barberini DJ; Freitas NP; Magnoni MS; Maia L; Listoni AJ; Heckler MC; Sudano MJ; Golim MA; da Cruz Landim-Alvarenga F; Amorim RM
    Stem Cell Res Ther; 2014 Feb; 5(1):25. PubMed ID: 24559797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.
    Barrachina L; Cequier A; Romero A; Vitoria A; Zaragoza P; Vázquez FJ; Rodellar C
    Stem Cell Res Ther; 2020 Feb; 11(1):52. PubMed ID: 32028995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.
    Ranera B; Antczak D; Miller D; Doroshenkova T; Ryan A; McIlwraith CW; Barry F
    Equine Vet J; 2016 Mar; 48(2):253-60. PubMed ID: 25582202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.
    Kamm JL; Parlane NA; Riley CB; Gee EK; Dittmer KE; McIlwraith CW
    PLoS One; 2019; 14(11):e0225161. PubMed ID: 31747418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.
    Schnabel LV; Abratte CM; Schimenti JC; Felippe MJ; Cassano JM; Southard TL; Cross JA; Fortier LA
    Regen Med; 2014; 9(5):621-35. PubMed ID: 24773530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility:
    Cequier A; Vázquez FJ; Vitoria A; Bernad E; Fuente S; Serrano MB; Zaragoza MP; Romero A; Rodellar C; Barrachina L
    Front Vet Sci; 2024; 11():1391872. PubMed ID: 38957800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.
    Barrachina L; Remacha AR; Romero A; Vázquez FJ; Albareda J; Prades M; Ranera B; Zaragoza P; Martín-Burriel I; Rodellar C
    Vet Immunol Immunopathol; 2016 Mar; 171():57-65. PubMed ID: 26964718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of equine bone marrow derived mesenchymal stem cells increases the expression of immunogenic genes.
    Barrachina L; Remacha AR; Romero A; Zaragoza P; Vázquez FJ; Rodellar C
    Vet Immunol Immunopathol; 2018 Jun; 200():1-6. PubMed ID: 29776607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice.
    Eliopoulos N; Stagg J; Lejeune L; Pommey S; Galipeau J
    Blood; 2005 Dec; 106(13):4057-65. PubMed ID: 16118325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of genes involved in immune response and in vitro immunosuppressive effect of equine MSCs.
    Remacha AR; Barrachina L; Álvarez-Arguedas S; Ranera B; Romero A; Vázquez FJ; Zaragoza P; Yañez R; Martín-Burriel I; Rodellar C
    Vet Immunol Immunopathol; 2015 Jun; 165(3-4):107-18. PubMed ID: 25977164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.
    Berglund AK; Fisher MB; Cameron KA; Poole EJ; Schnabel LV
    Front Vet Sci; 2017; 4():84. PubMed ID: 28660198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.
    Cequier A; Vázquez FJ; Romero A; Vitoria A; Bernad E; García-Martínez M; Gascón I; Barrachina L; Rodellar C
    Front Vet Sci; 2022; 9():957153. PubMed ID: 36337202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of novel murine epiphysis derived mesenchymal stem cells.
    Cheng CC; Lian WS; Hsiao FS; Liu IH; Lin SP; Lee YH; Chang CC; Xiao GY; Huang HY; Cheng CF; Cheng WT; Wu SC
    PLoS One; 2012; 7(4):e36085. PubMed ID: 22558340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-free human MSC medium supports consistency in human but not in equine adipose-derived multipotent mesenchymal stromal cell culture.
    Schubert S; Brehm W; Hillmann A; Burk J
    Cytometry A; 2018 Jan; 93(1):60-72. PubMed ID: 28926198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of continuous passage on the immunomodulatory properties of equine bone marrow-derived mesenchymal stem cells in vitro.
    Connard SS; Linardi RL; Even KM; Berglund AK; Schnabel LV; Ortved KF
    Vet Immunol Immunopathol; 2021 Apr; 234():110203. PubMed ID: 33636546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.
    Cassano JM; Schnabel LV; Goodale MB; Fortier LA
    Stem Cell Res Ther; 2018 Apr; 9(1):82. PubMed ID: 29615127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.